NCT05277636View on ClinicalTrials.gov

Acute Effects of R- and S-MDMA in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

January 13, 2024

Study Completion Date

January 13, 2024

Conditions
Healthy
Interventions
DRUG

3,4-methylenedioxymethamphetamine

A dose of 125 mg racemic MDMA will be administered.

DRUG

S-3,4-methylenedioxymethamphetamine

A dose of 125 mg enantiomeric S-MDMA will be administered.

DRUG

R-3,4-methylenedioxymethamphetamine (125 mg)

A dose of 125 mg enantiomeric R-MDMA will be administered.

DRUG

R-3,4-methylenedioxymethamphetamine (250 mg)

A dose of 250 mg enantiomeric R-MDMA will be administered.

OTHER

Placebo

Placebo (Mannitol)

Trial Locations (1)

Unknown

University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER